GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

GenVec, Inc. (Nasdaq: GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

GenVec will receive up to $2.3 million for the fourth year, which will support the generation of HIV vaccine candidates with GenVec's alternate adenovirus serotype technology.

www.genvec.com

Comments

  1. Carl Horton Carl Horton United States says:

    I'm very glad to hear that HIV vaccine is on the way now maybe I can live normal life. Can I please be notified upon realease of vaccine?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Does vaccine or infection induced immunity better protect against SARS-CoV-2 variants?